Recently, Professor Qiao Youlin's team of the Chinese Academy of Medical Sciences and Professor Xia Ningshao's team of Xiamen University published the 66 month follow-up results of the first domestic HPV vaccine cinquellin after immunization in the international academic journal Lancet Infectious diseases. Studies have shown that the vaccine has a protection rate of 100.0% against HPV16 / 18 related lesion endpoints within 5.5 years after immunization, and can induce high-level antibodies lasting for 5.5 years. The research team carried out a multicenter, randomized, double-blind and controlled trial based on five sites in China, and followed up 7372 healthy volunteers aged 18-45 years (3689 in the test group and 3683 in the control group) for 5.5 years. The results of follow-up analysis showed that in the population meeting the protocol set (PPS), the protection rate of the vaccine against the pathological endpoint related to HPV16 and / or HPV18 infection was 100.0%, and the protection efficacy was 100.0% in the age groups of 18-26 years and 27-45 years; The protective rate against HPV16 and / or 18 persistent infection (more than 6 months) was 97.3%, and the protective efficacy was 93.9% and 100.0% in the 18-26 and 27-45 age groups, respectively. In addition, during the whole study period, there were no serious adverse events related to vaccination, no pregnancy outcomes related to vaccination, and no abnormal neonatal health conditions. This research result confirms that Xinkening has excellent efficacy and safety in susceptible women aged 18-26 years and 27-45 years, and can effectively prevent HPV16 type and / or 18 type related cervical precancerous lesions and persistent infection. The follow-up results confirmed that Xinkening adopts the industrial technology system of E. coli prokaryotic expression virus like particle vaccine independently developed and created by China, which is characterized by stable process and small difference between product batches. (outlook new era)